Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA233025
Max Phase: Preclinical
Molecular Formula: C46H69N11O11S
Molecular Weight: 984.19
Molecule Type: Small molecule
Associated Items:
ID: ALA233025
Max Phase: Preclinical
Molecular Formula: C46H69N11O11S
Molecular Weight: 984.19
Molecule Type: Small molecule
Associated Items:
Synonyms (1): KNI-10161
Synonyms from Alternative Forms(1):
Canonical SMILES: CSCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1)C(C)C)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)O
Standard InChI: InChI=1S/C46H69N11O11S/c1-25(2)36(55-41(62)30(15-16-35(47)58)51-39(60)29-13-9-18-49-29)44(65)53-32(21-27-11-7-6-8-12-27)38(59)45(66)57-19-10-14-34(57)42(63)56-37(26(3)4)43(64)52-31(17-20-69-5)40(61)54-33(46(67)68)22-28-23-48-24-50-28/h6-8,11-12,23-26,29-34,36-38,49,59H,9-10,13-22H2,1-5H3,(H2,47,58)(H,48,50)(H,51,60)(H,52,64)(H,53,65)(H,54,61)(H,55,62)(H,56,63)(H,67,68)/t29-,30-,31-,32-,33-,34-,36-,37-,38-/m0/s1
Standard InChI Key: VJXOFNUAQFCRFQ-QTCJXMFWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 984.19 | Molecular Weight (Monoisotopic): 983.4899 | AlogP: -1.38 | #Rotatable Bonds: 27 |
Polar Surface Area: 336.24 | Molecular Species: ZWITTERION | HBA: 13 | HBD: 11 |
#RO5 Violations: 3 | HBA (Lipinski): 22 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.58 | CX Basic pKa: 9.50 | CX LogP: -4.53 | CX LogD: -4.57 |
Aromatic Rings: 2 | Heavy Atoms: 69 | QED Weighted: 0.05 | Np Likeness Score: -0.10 |
1. Kimura T, Nguyen JT, Maegawa H, Nishiyama K, Arii Y, Matsui Y, Hayashi Y, Kiso Y.. (2007) Chipping at large, potent human T-cell leukemia virus type 1 protease inhibitors to uncover smaller, equipotent inhibitors., 17 (12): [PMID:17448657] [10.1016/j.bmcl.2007.04.019] |
2. Nguyen JT, Zhang M, Kumada HO, Itami A, Nishiyama K, Kimura T, Cheng M, Hayashi Y, Kiso Y.. (2008) Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors., 18 (1): [PMID:18006315] [10.1016/j.bmcl.2007.10.066] |
3. Zhang M, Nguyen JT, Kumada HO, Kimura T, Cheng M, Hayashi Y, Kiso Y.. (2008) Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme., 16 (14): [PMID:18558491] [10.1016/j.bmc.2008.05.052] |
4. Zhang M, Nguyen JT, Kumada HO, Kimura T, Cheng M, Hayashi Y, Kiso Y.. (2008) Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties., 16 (10): [PMID:18400502] [10.1016/j.bmc.2008.03.055] |
Source(1):